

BiImmersion™: Biotech for the Non-Scientist

BiImmersion™: Biotech for the Non-Scientist is a three-day, in-depth course that delves into the scientific details on a broad number of biotechnology topics. BiImmersion is divided into three distinct sections: the fundamental biology upon which the healthcare industry is built; the science driving the innovative therapeutics that are saving lives; and the business of biopharma including drug discovery, development and manufacturing. Become fluent in the science and business of biopharma by taking this comprehensive course.

Five takeaways:

1. Fluency in the terminology and acronyms of the biopharma industry
2. Comprehensive scientific background needed to understand your company's, competitor's or client's products
3. Improved ability to communicate with scientists, regulators, colleagues and clients
4. Understanding of how a molecule moves from the lab to the marketplace
5. Innovative new developments within the biopharma industry

Course Agenda

Day One

Industry Overview 9:00-10:15

Biotechnology defined
Industry sectors
Categories and characteristics of drugs
Generics and biosimilars
Research support companies
Intersection of academia and industry

Break 10:15-10:30

Biology: Basis of Biopharma 10:30-11:30

Process of biotechnology
Cell structure and function
Molecules critical to life
Cellular communication: cell signaling
Industry application: antagonists and agonists

DNA: Biopharma's Blueprint 11:30-12:30

History of DNA discovery
DNA structure and function
DNA replication
DNA amplification: PCR
Chromosomes and genes
Lab: DNA isolation and extraction

Lunch 12:30-1:30

Proteins: Biopharma's Workhorse 1:30-2:45

How DNA codes for proteins
Protein structure
Post-translational modifications (PTM)
Industry application: PTM and making biologics
Protein folding
Chaperone therapeutics
Industry application: proteome and drug discovery

Break 2:45-3:00

Genetic Basis of Disease 3:00-4:15

Alleles

Dominant and recessive diseases

Activity: Genetic Taste Test

Mutations: source of genetic variation

Genetic basis of disease

Genome-wide association studies

Personalized medicine

Companion diagnostics

Pharmacogenomics

Q&A/Review 4:15-4:30

Day Two

Genomics: Understanding the Genetic Basis of Disease 9:00-10:30

Genomics defined

Non-coding DNA: the regulome

DNA microarrays (gene chips)

Applications of DNA microarrays

Next generation sequencing

Applications of next generation sequencing

From big data to rare disease

Third generation sequencing

Personalized medicine: integrating the 'omics

Comparative genomics

Lab: Microarray to Determine Drug Metabolism

Break 10:30-10:45

Treating Genetic Disease 10:45-12:00

RNA therapies: antisense, siRNA, microRNA, mRNA

Changing gene expression: exon-skipping therapy, gene therapy

Viral vectors

Genome editing: zinc finger nuclease, CRISPR/CAS9

Industry application: curing HIV

Lunch 12:00-1:00

Immunology & Infectious Disease 1:00-2:15

Immune system cells and tissues

Phases of the immune response

Non-specific immune response: inflammation

Industry application: understanding autoimmune disease

Specific immune response: T-cells and B-cells

Antibodies: structure and function

Cytotoxic T-cell structure and function

Helper T-cell structure and function

Vaccines: Activating an Immune Response

2:15-2:45

Immunological memory

How vaccines work

Types of vaccines: whole pathogen, subunit, DNA

Making the annual flu vaccines

Industry application: oncolytic vaccines

Industry application: HIV vaccine

Break 2:45-3:00

Immunotherapies: Biopharma's Therapeutic Powerhouse 3:00-4:15

Polyclonal and monoclonal antibodies

Making therapeutic antibodies: hybridomas, phage display, genetically engineered mice

Humanized vs. fully human antibodies

Therapeutic monoclonal antibodies: oncology, autoimmune disorders, infectious disease

Industry application: treating cholesterol with PCSK9 inhibitors

Bispecific antibodies

Antibody-drug conjugates

Immune system checkpoint inhibitor therapies

Chimeric antigen receptor therapies (CAR-T)

Controlling CAR-T

TCR therapies

Day Three

Making Biologics 9:00-10:15

Biologics vs. small molecule drugs
Recombinant DNA
Plasmids
Production platforms: bacteria and mammalian
Production platforms: animals and plants
Fusion protein therapeutics
Biosimilars: definition and approval pathway
Patents and data exclusivity

Break 10:15-10:30

Biomanufacturing 10:30-11:30

Cell line development
Cell bank production and qualification
Bulk upstream process: scale-up
Bulk downstream process: harvest
Purification: column chromatography
Formulation, fill and finish
Lab: column chromatography

Stem Cells and Regenerative Medicine

11:30-12:30

Stem cells properties
Promises and challenges
Induced pluripotent stem cells
Stem cells in the clinic
Organ and tissue replacement

Lunch 12:30-1:30

Drug Discovery 1:30-2:30

Rational drug discovery
Target identification and validation
Therapeutic options
Assay development
High throughput screening (HTS)
In vitro safety and efficacy testing
Biomarkers

Break 2:30-2:45

Drug Development 2:45-3:45

Regulatory agencies
Preclinical studies
Clinical trials
Pharmacovigilance
Drug development timeline
Desirable FDA designations
Orphan drugs

Newly Approved and In Development 3:45-4:15

Microbiome and related therapies
Circulating tumor cells: detection and capture
Curing hepatitis C
Liquid biopsies
Exosome-based therapeutics
Epigenetic medicine and diagnostics
Overcoming antibiotic resistance: bacteriophage

Wrap Up and Evaluation 4:15-4:30